Ongoing clinical trials are further evaluating the prognostic and predictive value of ERG fusions in prostate cancer patients at different stages of the disease or during treatment (e.g., trials evaluating the AR signaling inhibitors enzalutamide and apalutamide, PSMA theranostics, brachytherapy; see ClinicalTrials.gov for reference) and include the analysis of ERG fusion status both in primary and secondary outcome measures. The gene discussed is AR; the disease is prostate cancer.